Closed Studies

A Screening Study of Patients with Breast Cancer to Evaluate Urine PGE-M Levels and COX-2 Expression in Tumor Samples


Ella Looper The Methodist Hospital Research Institute, Houston, Texas

Study Review

This study will collect the PGE-M and COX-2 IHC levels in subjects with breast cancer to establish whether urinary PGE-M can be used as a surrogate marker for increased COX-2 expression.

1. The primary objective is to determine the level of PGE-M in the urine of breast cancer patients.
2. The secondary objective is to correlate PGE-M expression in urine expression of COX-2 through IHC in tumor tissue.
3. The third objective is to test the difference in urinary PGE-M level between the patients with tumor and patients without tumor.

To pursue above mentioned hypothesis and aims, we plan to study female patients ≥18 years of age with either metastatic or early stage breast cancer with intact tumor and patients who have been recently diagnosed with breast cancer and are currently tumor-free.

One urine sample and one tumor sample from tumor paraffin blocks (5 slides minimum) will be taken from approximately 340 breast cancer patients according to the following scheme:
80 Her2/neu positive by IHC or FISH positive (any ER/PR) patients
80 ER+ and/or PR+ patients/Her2/neu negative by IHC or FISH negative
80 triple negative patients (Her2/neu negative by IHC or FISH negative, ER-, PR)
100 recently diagnosed patients who have had surgical resection and have no tumor present to serve as negative controls, no specific Her2/neu or ER/PR receptor status is required from this group of patients.



Love Research Army

We combat the disparities that exist in research by challenging the scientific community to launch studies that are as inclusive and diverse as the people that breast cancer affects.

En Español »